| Experimental (n = 48) | Control (n = 41) |  |  |
---|---|---|---|---|
n (%) | n (%) | X2 | P | |
Gendera | Â | Â | 0.48 | 0.49 |
 Male | 7 (14.6) | 4 (9.8) |  |  |
 Female | 41 (85.4) | 37 (90.2) |  |  |
 |  |  | Z | P |
Previous observe CHb |  |  | −0.94 | 0.35 |
 None | 1 (2.1) | 0 (0.0) |  |  |
 1–5 | 10 (20.8) | 5 (12.2) |  |  |
 6–10 | 8 (16.7) | 9 (22.0) |  |  |
 11–15 | 5 (10.4) | 7 (17.1) |  |  |
 16–20 | 7 (14.6) | 1 (2.4) |  |  |
  > 20 | 17 (35.4) | 19 (46.3) |  |  |
Previous perform CHb |  |  | −0.28 | 0.78 |
 None | 22 (45.8) | 16 (39.0) |  |  |
 1–5 | 23 (47.9) | 25 (61.0) |  |  |
 6–10 | 3 (6.3) | 0 (0.0) |  |  |
 | M (SD) | T | P | |
Agec | 23.50 (1.41) | 23.34 (0.97) | −0.61 | 0.55 |
Baseline self-efficacyc | 25.60 (12.95) | 27.12 (13.21) | 0.55 | 0.59 |